Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.
Imedex is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
Imedex®, LLC designates this live educational activity for a maximum of 8.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity enables a participant to earn up to 8.5 MOC points towards the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.
Who Should Attend
This live activity is specifically designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) who are involved and/or interested in the treatment of patients with MPN and MDS.
After successful completion of this activity, participants should be able to:
- Evaluate molecular and genetic abnormalities, their role in pathology of disease, and how they can potentially be utilized to enhance diagnostic, prognostic, and therapeutic strategies to enhance outcomes in patients with MPN or MDS
- Interpret finalized and ongoing clinical trial data utilizing standard of care and/or investigational therapies for the optimal treatment and management of patients with MPN or MDS
- Recognize disease- and therapy-associated adverse events and formulate strategies for their management
- Assess strategies for managing patients with MPN or MDS who are intolerant or develop resistance to therapy
- Formulate optimal evidence-based strategies for the management of patients with MPN or MDS that take into consideration disease stage, cytogenetic analysis, and patient risk factors